STUART KAHN, M.D.
Medical Practice at 56 Ave, Seattle, WA
License number
Washington MD 00024361
Category
Medical Practice
Type
Pediatric Rheumatology
Address
Address
7013 56Th Ave NE, Seattle, WA 98115
Phone
(206) 524-0214
Personal information
See more information about STUART KAHN at radaris.comName
Address
Phone
7013 56Th Ave NE, Seattle, WA 98115
7013 56Th Ave NE, Seattle, WA 98115
2514 11Th Ave W, Seattle, WA 98119
7013 56Th St, Seattle, WA 98115
4822 48Th St, Seattle, WA 98118
Professional information
Dr. Stuart J Kahn, Seattle WA - MD (Doctor of Medicine)
Specialties:
Pediatric Rheumatology
Address:
Dv Immun-Rheum SUITE PEDS, Seattle 98195
(206) 543-4424 (Phone), (206) 543-3184 (Fax)
(206) 543-4424 (Phone), (206) 543-3184 (Fax)
Certifications:
Pediatric Rheumatology, 1994, Pediatrics, 1998
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Medicine And Dentistry of New Jersey / Newark
Graduated: 1985
Chldns Hosp Med Ctr-U Wash
University of Medicine And Dentistry of New Jersey / Newark
Graduated: 1985
Chldns Hosp Med Ctr-U Wash
Pharmaceutical Composition Comprising Racemic Aminopterin
US Patent:
2010019, Jul 29, 2010
Filed:
Jan 23, 2010
Appl. No.:
12/692593
Inventors:
John A. Zebala - Sammamish WA, US
Dean Y. Maeda - Seattle WA, US
Joel R. Morgan - Kent WA, US
Stuart J. Kahn - Seattle WA, US
Dean Y. Maeda - Seattle WA, US
Joel R. Morgan - Kent WA, US
Stuart J. Kahn - Seattle WA, US
International Classification:
A61K 31/519, C07D 475/08, A61P 19/02, A61P 17/00, A61P 1/00, A61P 35/02, A61P 35/00
US Classification:
514249, 544260
Abstract:
There is disclosed a pharmaceutical composition comprising racemic aminopterin or pharmaceutically acceptable salts thereof. There is further disclosed a method to treat a disorder in a patient comprising administering a therapeutically effective amount of racemic aminopterin or pharmaceutically acceptable salts of racemic aminopterin. More particularly, there is disclosed a method for treating disorders modulated by at least dihydrofolate reductase activity, such as cancers and inflammatory disorders, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of racemic aminopterin or a pharmaceutically acceptable salt thereof.